
Proceedings Paper
Antimicrobial activity of new porphyrins of synthetic and natural originFormat | Member Price | Non-Member Price |
---|---|---|
$17.00 | $21.00 |
Paper Abstract
Antimicrobial photodynamic inactivation has been successfully used against Gram (+) microorganisms, but most of the
photosensitizers (PSs) on Gram (-) bacteria acts weakly. PSs are the natural or synthetic origin dyes, mainly porphyrins.
We have synthesized more than 100 new cationic porphyrins and metalloporphyrins with different functional groups
(hydroxyethyl, butyl, allyl, methallyl) and metals (cobalt, iron, copper, zinc, silver and other); from the nettle have also
been purified pheophytin (a+b) and pheophytin (a) and have synthesized their Ag-and Zn-metalloporphyrins. It was
found that in the dark (cytotoxic) mode, the most highly efficiency against microorganisms showed Agmetalloporphyrins
of both types of porphyrins (synthetic and natural). Metalloporphyrin of natural origin Ag-pheophytin
(a + b) is a strong antibacterial agent and causes 100% death as the Gram (+) microorganisms (St. aureus and MRSA) and
the Gram (-) microorganisms (E.coli and Salmonella). It is established that for the destruction of Gram (+) and Gram (-)
microorganisms in photodynamic mode cationic water-soluble synthetic metalloporphyrins, especially Zn-TBut4PyP,
many times more effective than pheophytins. In vivo conditions on mice established that the best therapeutic activity
against various strains of the microorganism St. aureus has the synthetic metalloporphyrin Ag-TBut4PyP. It is
significantly more efficient than known drug "Chlorophyllipt" (2.5-3 times) and leads the survival rate of animals up to
50-60%.
Paper Details
Date Published: 1 March 2012
PDF: 9 pages
Proc. SPIE 8211, Mechanisms for Low-Light Therapy VII, 821107 (1 March 2012); doi: 10.1117/12.908634
Published in SPIE Proceedings Vol. 8211:
Mechanisms for Low-Light Therapy VII
Michael R. Hamblin; Juanita Anders; James D. Carroll, Editor(s)
PDF: 9 pages
Proc. SPIE 8211, Mechanisms for Low-Light Therapy VII, 821107 (1 March 2012); doi: 10.1117/12.908634
Show Author Affiliations
Grigor V. Gyulkhandanyan, Institute of Biochemistry (Armenia)
Robert K. Ghazaryan, Yerevan State Medical Univ. (Armenia)
Marina H. Paronyan, Institute of Biotechnology (Armenia)
Robert K. Ghazaryan, Yerevan State Medical Univ. (Armenia)
Marina H. Paronyan, Institute of Biotechnology (Armenia)
Ghukas I. Ulikhanyan, Armenian Pharmaceutical Association (Armenia)
Aram G. Gyulkhandanyan, Institute of Biochemistry (Armenia)
Lida A. Sahakyan, Yerevan State Medical Univ. (Armenia)
Aram G. Gyulkhandanyan, Institute of Biochemistry (Armenia)
Lida A. Sahakyan, Yerevan State Medical Univ. (Armenia)
Published in SPIE Proceedings Vol. 8211:
Mechanisms for Low-Light Therapy VII
Michael R. Hamblin; Juanita Anders; James D. Carroll, Editor(s)
© SPIE. Terms of Use
